METAVONE LIMITED
ACN 101 733 920

SUPPLEMENTARY PROSPECTUS

IMPORTANT INFORMATION

This Supplementary Prospectus ("Supplementary Prospectus") is dated 16 September 2016 and is supplementary to the prospectus dated 5 September 2016 ("Original Prospectus") issued by Metavone Limited ACN 101 733 920 ("Company" or "Metavone").

This Supplementary Prospectus was lodged with the Australian Securities and Investments Commission ("ASIC") on 16 September 2016. Neither the ASIC nor the ASX Limited ("ASX") takes any responsibility as to the contents of this Supplementary Prospectus.

This Supplementary Prospectus must be read together with the Original Prospectus. To the extent of any inconsistency between this Supplementary Prospectus and the Original Prospectus, the provisions of this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Original Prospectus have the same meaning in this Supplementary Prospectus.

This Supplementary Prospectus may be accessed on the Company's website at www.metavone.com.au. The Company will send a copy of this Supplementary Prospectus to all applicants who have subscribed for Shares pursuant to the Original Prospectus.

New applications for Shares may only be made on the Application Forms accompanying or attached to this Supplementary Prospectus.
1. **REASONS FOR THIS SUPPLEMENTARY PROSPECTUS**

The purpose of this Supplementary Prospectus is to provide additional information as a consequence of matters raised by ASIC in relation to the Original Prospectus.

2. **CONTENT SUPPLEMENTED**

The Original Prospectus is amended or supplemented as set out below.

2.1 **Amended Indicative Timetable (Section 1 of Original Prospectus)**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated Priority Offer Closing Date (as extended)</td>
<td>14 October 2016</td>
</tr>
<tr>
<td>Estimated Public Offer Closing Date (as extended)</td>
<td>21 October 2016</td>
</tr>
<tr>
<td>Expected issue of Shares under Prospectus</td>
<td>26 October 2016</td>
</tr>
<tr>
<td>Expected despatch of holding statements</td>
<td>28 October 2016</td>
</tr>
<tr>
<td>Expected date for Shares commencing trading on ASX</td>
<td>4 November 2016</td>
</tr>
</tbody>
</table>

The above dates are indicative only and may change without notice. The Company reserves the right to extend the Closing Dates or close the Offers early without notice which may have a consequential effect on the other events in the indicative timetable.

2.2 **Referencing of Statements (Section 4 of Original Prospectus)**

(a) In Section 4.3 of the Original Prospectus at page 26 there are statements of various "targets identified" associated with dementia in respect of the Company's isoflavone compounds. The references for these "targets identified" are set out below.

<table>
<thead>
<tr>
<th>Target Identified</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipoxigenase</td>
<td>Joshi &lt;br&gt; <em>The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease</em>&lt;br&gt; <em>Trends in Pharmacological Sciences 2015</em></td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td>Wroolie &lt;br&gt; <em>Cognitive effects of hormone therapy continuation or discontinuation in a sample of women at risk for Alzheimer's disease</em>&lt;br&gt; <em>The American Journal of Geriatric Psychiatry 2015</em></td>
</tr>
<tr>
<td>Microtubule-associated protein tau</td>
<td>Iqbal &lt;br&gt; <em>Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.</em>&lt;br&gt; <em>Expert opinion on therapeutic targets 2014</em></td>
</tr>
<tr>
<td>Protein kinases</td>
<td>Martin &lt;br&gt; <em>Tau protein kinases: involvement in Alzheimer's disease.</em>&lt;br&gt; <em>Ageing research reviews 2013</em></td>
</tr>
<tr>
<td>Protein Name</td>
<td>Author</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Beta-secretase 1</td>
<td>Martin</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidermal growth factor receptor</td>
<td>Wang</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophage colony stimulating factor 1</td>
<td>Dagher</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid receptor</td>
<td>Lante</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione reductase</td>
<td>Saharan</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitric oxide synthase</td>
<td>Mukherjee</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(b) In Section 4.5 of the Original Prospectus at page 28 there is a diagram titled "Estimated New Cancer Cases Worldwide (including Prostate, Breast and Ovarian Cancers) for Leading Cancer Sites, 2012". This diagram is taken from "Global Cancer Facts & Figures 3rd Edition, 2015, American Cancer Society".

(c) In Section 4.6 of the Original prospectus at page 28 there is a statement "One Japanese study found that a diet containing a high proportion of soybean and soybean products was associated with reduced risk of dementia". The study referred to is "Ninomiya - Patterns of Japanese Diet and Risk of Dementia. Current Nutrition Reports 2015".

(d) In Section 4.6 of the Original Prospectus at page 29 there is a statement "Another study suggested isoflavone supplements can improve cognitive function in postmenopausal women". The study referred to is "Cheng - Do soy isoflavones..."
improve cognitive function in postmenopausal women? A meta-analysis. Menopause 2015".

(e) In Section 4.6 of the Original Prospectus at page 29 there is a statement "Flavonoids derived from grape seed extract have also been shown to reduce the tangling of tau protein in mouse models of Alzheimer's disease". The reference for this statement is "Wang - Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease, Journal of Alzheimers Disease 2010 and Bulic - Tau protein and tau aggregation inhibitors, Neuropharmacology 2010".

2.3 Supplementary Investigating Accountant's Report (Section 8 of Original Prospectus)

Rothsay Consulting Services Pty Ltd has prepared a Supplementary Investigating Accountant's Report for inclusion with this Supplementary Prospectus as Annexure "A". The Supplementary Investigating Accountant's Report should be read in conjunction with the Investigating Accountant's Report in Section 8 of the Original Prospectus.

The Supplementary Investigating Accountant's Report refers to the auditor issuing modified audit opinions on the financial reports of the Company for the years ended 30 June 2014, 30 June 2015 and the period ended 29 February 2016 as they included emphases of matter regarding the Company's ability to continue as a going concern. The Investigating Accountant in the Supplementary Investigating Accountant's Report considers these emphases of matter will be satisfied if the Company is successful in achieving the minimum raising under the Prospectus.

The financial reports of the Company for the years ended 30 June 2014, 30 June 2015 and the period ended 29 February 2016 have been lodged with ASIC and are taken to be incorporated by reference in this Supplementary Prospectus in accordance with section 712 of the Corporations Act. The Company will give a copy of these incorporated documents free of charge to any person during the application period of the Offer by the Original Prospectus as amended by this Supplementary Prospectus.

3. NEW APPLICATIONS

All new Applications for Shares after the date of this Supplementary Prospectus must be made using the relevant Application Form (for the Priority Offer or the Public Offer) attached to or accompanying this Supplementary Prospectus. The Application Forms contain instructions on how it is to be completed.

Applications after the date of this Supplementary Prospectus must not be made on the Application Forms attached to or accompanying the Original Prospectus.

4. CONSENTS TO BE NAMED

Rothsay Consulting Services Pty Ltd has given, and has not, before the date of this Supplementary Prospectus, withdrawn its consent to the inclusion of its Supplementary Investigating Accountant's Report in this Supplementary Prospectus.

Rothsay Auditing Chartered Accountants has given, and has not, before the date of this Supplementary Prospectus, withdrawn its consent to the reference in this Supplementary Prospectus to the audited financial information of the Company.
5. **DIRECTORS’ AUTHORISATION**

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with the ASIC.

Dr Stuart Gunzburg  
Managing Director  
for and on behalf of  
Metavone Limited
16th September 2016

The Directors
Metavone Limited
159 Stirling Highway
Nedlands WA 6009

Dear Directors

SUPPLEMENTARY INVESTIGATING ACCOUNTANT’S REPORT

1. Introduction

Rothsay Consulting Services Pty Ltd (‘Rothsay’) prepared an Investigating Account’s Report dated 31 July 2016 (‘Our IAR’) for inclusion in a prospectus prepared by Metavone Limited (‘Metavone’ or ‘the Company’).

This Report has been prepared as a supplementary IAR for inclusion in a supplementary prospectus to be prepared by Metavone and should be read in conjunction with our IAR.

2. Audit Opinions

The following historical and historical pro-forma financial information (together the ‘Historical Financial Information’) of Metavone was included in our IAR:

- the statement of financial position of Metavone as at 29 February 2016;
- the-pro forma statement of financial position of Metavone as at 29 February 2016 adjusted to include funds to be raised by the Prospectus;
- the statements of financial performance for the years ended 30 June 2014 and 30 June 2015 and the period ended 29 February 2016; and
- the statements of cash flows for the years ended 30 June 2014 and 30 June 2015 and the period ended 29 February 2016.

The Historical Financial Information has been extracted from the financial reports of Metavone for the years ended 30 June 2014, 30 June 2015 and the period ended 29 February 2016, which were audited by Rothsay Auditing in accordance with the Australian Auditing Standards. Rothsay Auditing issued modified audit opinions on the financial reports in that they each included emphases of matter regarding the Company’s ability to continue as a going concern. In our opinion these emphases of matter will be satisfied if the Company is successful in achieving the minimum raising under the Prospectus.

3. Subsequent Events

The 29 February 2016 audited financial statements are the most current that have been prepared by the Company. The pro-forma statement of financial position as at 29 February 2016 included in our IAR reflects the funds to be raised under the Prospectus and the impact of any material transactions and events that have occurred subsequent to that date.
Based upon the procedures we have performed, and having regard to the scope of this Report and the information provided by the Directors, to the best of our knowledge and belief no material transaction, event outside of the ordinary business of Metavone or change to the ordinary business of Metavone, has come to our attention that would require comment on, or adjustment to, the information referred to in our IAR or that would cause such information to be misleading or deceptive.

4. Disclosures

Rothsay Consulting Services Pty Ltd has consented to the inclusion of this Report in the Supplementary Prospectus in the form and context in which it is included. At the date of this Report this consent has not been withdrawn.

Yours faithfully

Rothsay Consulting Services Pty Ltd

Graham R Swan FCA MAICD
Director
**Supplementary Prospectus - Priority Offer Application Form**

**This document is important. If you are in doubt as to how to deal with it, please contact your stockbroker or licensed professional advisor.**

**All Correspondence to:**

Security Transfer Registrars Pty Ltd  
PO BOX 535, APPLECROSS WA 6953  
770 Canning Highway, APPLECROSS WA 6153  
T: +61 8 9315 2333  F: +61 8 9315 2233  
E: registrar@securitytransfer.com.au  
W: www.securitytransfer.com.au

**PLEASE READ CAREFULLY ALL INSTRUCTIONS ON THE REVERSE OF THIS FORM**

This application relates to the offer of Fully Paid Ordinary Shares at the price of $0.20 per Share. No share will be issued pursuant to the Prospectus and the Supplementary Prospectus later than 13 months after the date of the Prospectus. Before completing this Application Form you should read the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 and the instructions overleaf. Please print in BLOCK LETTERS.

---

<table>
<thead>
<tr>
<th>Full Name of Applicant / Company</th>
<th>I / We apply for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title (e.g.: Dr, Mrs) Given Name(s) or Company Name</td>
<td>I / We lodge full application of monies of:</td>
</tr>
<tr>
<td></td>
<td>shares at AUD $0.20 per share</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Joint Applicant #2</th>
<th>I / We apply for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title (e.g.: Dr, Mrs) Given Name(s) or Company Name</td>
<td>I / We lodge full application of monies of:</td>
</tr>
<tr>
<td></td>
<td>shares at AUD $0.20 per share</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Joint Applicant #3</th>
<th>I / We apply for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title (e.g.: Dr, Mrs) Given Name(s) or Company Name</td>
<td>I / We lodge full application of monies of:</td>
</tr>
<tr>
<td></td>
<td>shares at AUD $0.20 per share</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Account Designation (for example: THE SMITH SUPERFUND A/C)</th>
<th>I / We apply for:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I / We lodge full application of monies of:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I / We apply for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>shares at AUD $0.20 per share</td>
</tr>
</tbody>
</table>

| or such lesser number of shares which may be allocated to me/us by the Directors. |

---

**Declaration and Statements:**

1. I / We declare that all details and statements made by me/us are complete and accurate.

2. I / We agree to be bound by the Terms & Conditions set out in the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 and by the Constitution of the Company.

3. I / We authorise the Company to complete and execute any documentation necessary to effect the issue of Securities to me/us.

4. I / We have received personally a copy of the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 accompanied by or attached to this Application form, or a copy of the Application Form or a direct derivative of the Application Form before applying for the Securities.

5. I / We acknowledge that the Company will send me/us a paper copy of the Prospectus and any Supplementary Prospectus (if applicable) free of charge if I / We request so during the currency of the Prospectus and the Supplementary Prospectus.

6. I / We acknowledge that returning the Application Form with the application monies will constitute my/our offer to subscribe for Securities in the Company and that no notice of acceptance of the application will be provided.

---

**MTV IPOAPP2016**

---
APPLICATION FORMS

Please complete all parts of the Application Form using BLOCK LETTERS. Use correct forms of registrable name (see below). Applications using the wrong form of name may be rejected. Current CHESS participants should complete their name and address in the same format as they are presently registered in the CHESS system.

Insert the number of Shares you wish to apply for. The application must be for a minimum of 10,000 Shares and thereafter in multiples of 1,000 Shares. The applicant(s) agree(s) upon and subject to the terms of the Prospectus to take any number of Shares equal to or less than the number of Shares indicated on the Application Form that may be allotted to the applicants pursuant to the Prospectus and declare(s) that all details of statements made are complete and accurate.

No notice of acceptance of the application will be provided by the Company prior to the allotment of Shares. Applicants agree to be bound upon acceptance by the Company of the application.

Please provide us with a telephone contact number (including the person responsible in the case of an application by a company) so that we can contact you promptly if there is a query in your Application Form. If your Application Form is not completed correctly, it may still be treated as valid. There is no requirement to sign the Application Form. The Company's decision as to whether to treat your application as valid, and how to construe, amend or complete it shall be final.

PAYMENT

BPAY® your payment via internet or phone banking.
A unique BPAY reference number was provided in the Priority Offer Letter to Shareholders. If you have misplaced the Priority offer Letter then please contact our share registry to obtain your unique BPAY reference number.

Applicants should be aware of their financial institution's cut-off time (the time payment must be made to be processed overnight) and ensure payment is processed by their financial institution on or before the day prior to the closing date of the offer.

BPAY applications will only be regarded as accepted if payment is received by the registry from your financial institution or on or prior to the closing date. It is the applicant's responsibility to ensure funds are submitted correctly by the closing date and time.

You do not need to return any documents if you have made payment via BPAY.
Your BPAY reference number will process your payment to your application electronically and you will be deemed to have applied for such securities for which you have paid.

All cheques should be made payable to METAVONE LIMITED – SHARE OFFER ACCOUNT and drawn on an Australian bank and expressed in Australian currency and crossed “Not Negotiable”. Cheques or bank drafts drawn on overseas banks in Australian or any foreign currency will NOT be accepted. Any such cheques will be returned and the acceptance deemed to be invalid.

Sufficient cleared funds should be held in your account as your acceptance may be rejected if your cheque is dishonoured. Do not forward cash as receipts will not be issued.

LODGING OF APPLICATIONS

Completed Application Forms and cheques must be:

Posted to:
METAVONE LIMITED
C/- Security Transfer Registrars Pty Ltd
PO Box 535
APPLECROSS WA 6953

Delivered to:
METAVONE LIMITED
C/- Security Transfer Registrars Pty Ltd
770 Canning Highway
APPLECROSS WA 6153

Applications must be received by no later than 5.00pm on the Priority Offer Closing Date 14 October 2016 which may be changed immediately after the Opening Date at any time and at the discretion of the Company.

CHESS HIN/BROKER SPONSORED APPLICANTS

The Company intends to become an Issuer Sponsored participant in the ASX CHESS System. This enables a holder to receive a statement of holding rather than a certificate. If you are a CHESS participant (or are sponsored by a CHESS participant) and you wish to hold shares allotted to you under this Application on the CHESS subregister, enter your CHESS HIN. Otherwise, leave this box blank and your Shares will automatically be Issuer Sponsored on allotment.

CORRECT FORM OF RegistrABLE TITLE

Note that only legal entities are allowed to hold securities. Applications must be in the name(s) of a natural person(s), companies or other legal entities acceptable to Metavone Limited. At least one full given name and the surname are required for each natural person. The name of the beneficiary or any other non-registrable name may be included by way of an account designation if completed exactly as described in the example of the correct forms of registrable names below:

**TYPE OF INVESTOR**

<table>
<thead>
<tr>
<th>CORRECT</th>
<th>INCORRECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>Mr John Alfred Smith</td>
</tr>
<tr>
<td>Company</td>
<td>ABC Pty Ltd</td>
</tr>
<tr>
<td>Joint Holdings</td>
<td>Mr Peter Robert Williams &amp; Ms Louise Susan Williams</td>
</tr>
<tr>
<td>Trusts</td>
<td>Mrs Susan Jane Smith</td>
</tr>
<tr>
<td>&lt;Sue Smith Family A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Deceased Estates</td>
<td>Mr John Alfred Smith</td>
</tr>
<tr>
<td>&lt;Estate John Smith A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Minor (a person under the age of 18)</td>
<td>Mr John Robert Smith</td>
</tr>
<tr>
<td>&lt;Peter Smith A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Partnerships</td>
<td>Mr Michael John Smith</td>
</tr>
<tr>
<td>&lt;John Smith and Son A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Superannuation Funds</td>
<td>Jane Smith Pty Ltd</td>
</tr>
<tr>
<td>&lt;Super Fund A/C&gt;</td>
<td></td>
</tr>
</tbody>
</table>

Supplementary Prospectus dated 16 September 2016.

This Application Form relates to the Offer of Fully Paid Shares in Metavone Limited pursuant to the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016.
This application relates to the offer of Fully Paid Ordinary Shares at the price of $0.20 per Share.

No share will be issued pursuant to the Prospectus and the Supplementary Prospectus later than 13 months after the date of the Supplementary Prospectus.

Before completing this Application Form you should read the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 and the instructions overleaf. Please print in BLOCK LETTERS.

I / We apply for:

I/We lodge full application of monies of:

A $

or such lesser number of shares which may be allocated to me/us by the Directors.

BPAY® this payment via internet or phone banking. Please visit our share registry's website: www.securitytransfer.com.au and complete the online application form located under the tab “Online IPO Applications” on the share registry’s home page. If electronic payment cannot be made then cheque(s) or bank draft(s) can be used. See reverse for further payment instructions.

Full Name of Applicant / Company
Title (e.g.: Dr, Mrs) Given Name(s) or Company Name

Joint Applicant #2
Title (e.g.: Dr, Mrs) Given Name(s) or Company Name

Joint Applicant #3
Title (e.g.: Dr, Mrs) Given Name(s) or Company Name

Account Designation (for example: THE SMITH SUPERFUND A/C)

Postal Address
Unit
Street Number
Street Name or PO BOX
Suburb / Town / City
State
Postcode
Country Name (if not Australia)

CHES HIN (where applicable)

If an incorrect CHESS HIN has been provided (for example, an incorrect number as registration details do not match those registered) any securities issued will be held on the Issuer Sponsored subregister.

Tax File Number / Australian Business Number

Contact Name

Contact Number

Email Address

Declaration and Statements:
1) I / We declare that all details and statements made by me/us are complete and accurate.
2) I / We agree to be bound by the Terms & Conditions set out in the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 and by the Constitution of the Company.
3) I / We authorise the Company to complete and execute any documentation necessary to effect the issue of Securities to me/us.
4) I / We have received personally a copy of the Prospectus dated 5 September 2016 and the Supplementary Prospectus dated 16 September 2016 accompanied by or attached to this Application form, or a copy of the Application Form or a direct derivative of the Application Form before applying for the Securities.
5) I / We acknowledge that the Company will send me/us a paper copy of the Prospectus and any Supplementary Prospectus (if applicable) free of charge if I/we request so during the currency of the Prospectus and the Supplementary Prospectus.
6) I / We acknowledge that returning the Application Form with the application monies will constitute my/our offer to subscribe for Securities in the Company and that no notice of acceptance of the application will be provided.
APPLICATION FORMS
Please complete all parts of the Application Form using BLOCK LETTERS. Use correct forms of registrable name (see below). Applications using the wrong form of name may be rejected. Current CHESS participants should complete their name and address in the same format as they are presently registered in the CHESS system.

Insert the number of Shares you wish to apply for. The application must be for a minimum of 10,000 Shares and thereafter in multiples of 1,000 Shares. The applicant(s) agree(s) upon and subject to the terms of the Prospectus to take any number of Shares equal to or less than the number of Shares indicated on the Application Form that may be allotted to the applicants pursuant to the Prospectus and declare(s) that all details of statements made are complete and accurate.

No notice of acceptance of the application will be provided by the Company prior to the allotment of Shares. Applicants agree to be bound upon acceptance by the Company of the application.

Please provide us with a telephone contact number (including the person responsible in the case of an application by a company) so that we can contact you promptly if there is a query in your Application Form. If your Application Form is not completed correctly, it may be still be treated as valid. There is no requirement to sign the Application Form. The Company's decision as to whether to treat your application as valid, and how to construe, amend or complete it shall be final.

PAYMENT
www.securitytransfer.com.au
BPAY® your payment via internet or phone banking. Please visit our share registry’s website: www.securitytransfer.com.au and complete the online application form located under the tab “Online IPO Applications” on the share registry’s home page. All online applicants can BPAY their payments via internet or phone banking. A unique reference number will be quoted upon completion of the application.

Applicants should be aware of their financial institution's cut-off time (the time payment must be made to be processed overnight) and ensure payment is processed by their financial institution on or before the day prior to the closing date of the offer.

BPAY applications will only be regarded as accepted if payment is received by the registry from your financial institution on or prior to the closing date. It is the applicant's responsibility to ensure funds are submitted correctly by the closing date and time.

You do not need to return any documents if you have made payment via BPAY.

Your BPAY reference number will process your payment to your application electronically and you will be deemed to have applied for such securities for which you have paid.

All cheques should be made payable to METAVONE LIMITED – SHARE OFFER ACCOUNT and drawn on an Australian bank and expressed in Australian currency and crossed "Not Negotiable". Cheques or bank drafts drawn on overseas banks in Australian or any foreign currency will NOT be accepted. Any such cheques will be returned and the acceptance deemed to be invalid. Sufficient cleared funds should be held in your account as your acceptance may be rejected if your cheque is dishonoured. Do not forward cash as receipts will not be issued.

LODGING OF APPLICATIONS
Completed Application Forms and cheques must be:

Posted to:
METAVONE LIMITED
C/- Security Transfer Registrars Pty Ltd
PO Box 535
APPLECROSS WA 6953

OR

Delivered to:
METAVONE LIMITED
C/- Security Transfer Registrars Pty Ltd
770 Canning Highway
APPLECROSS WA 6153

Applications must be received by no later than 5.00pm on the Public Offer Closing Date 21 October 2016 which may be changed immediately after the Opening Date at any time and at the discretion of the Company.

CHESS HIN/BROKER SPONSORED APPLICANTS
The Company intends to become an Issuer Sponsored participant in the ASX CHESS System. This enables a holder to receive a statement of holding rather than a certificate. If you are a CHESS participant (or are sponsored by a CHESS participant) and you wish to hold shares allotted to you under this Application on the CHESS subregister, enter your CHESS HIN. Otherwise, leave this box blank and your Shares will automatically be Issuer Sponsored on allotment.

CORRECT FORM OF REGISTRABLE TITLE
Note that only legal entities are allowed to hold securities. Applications must be in the name(s) of a natural person(s), companies or other legal entities acceptable to Metavone Limited. At least one full given name and the surname are required for each natural person. The name of the beneficiary or any other non-registrable name may be included by way of an account designation if completed exactly as described in the example of the correct forms of registrable names below:

<table>
<thead>
<tr>
<th>TYPE OF INVESTOR</th>
<th>CORRECT</th>
<th>INCORRECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>Mr John Alfred Smith</td>
<td>J A Smith</td>
</tr>
<tr>
<td>Use given names in full, not initials.</td>
<td>ABC Pty Ltd</td>
<td>ABC Pty Ltd</td>
</tr>
<tr>
<td>Company</td>
<td>Mr Peter Robert Williams &amp; Ms Louise Susan Williams</td>
<td>Peter Robert &amp; Louise S Williams</td>
</tr>
<tr>
<td>Use the company’s full title, not abbreviations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint Holdings</td>
<td>Mrs Susan Jane Smith</td>
<td>Sue Smith Family Trust</td>
</tr>
<tr>
<td>Use full and complete names.</td>
<td>&lt;Sue Smith Family A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Trusts</td>
<td>Ms Jane Mary Smith &amp; &amp; Mr Frank William Smith</td>
<td>Estate of Late John Smith or &amp; John Smith Deceased</td>
</tr>
<tr>
<td>Use trustee(s) personal name(s), Do not use the name of the trust.</td>
<td>&lt;Sue Smith Family A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Deceased Estates</td>
<td>Mr John Alfred Smith &amp;</td>
<td>Master Peter Smith</td>
</tr>
<tr>
<td>Use the executor(s) personal name(s).</td>
<td>&lt;Peter Smith A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Minor (a person under the age of 18)</td>
<td>Mr John Alfred Smith</td>
<td>John Smith and Son</td>
</tr>
<tr>
<td>Use the name of a responsible adult with an appropriate designation.</td>
<td>&lt;Peter Smith A/C&gt;</td>
<td></td>
</tr>
<tr>
<td>Partnerships</td>
<td>Mr John Robert Smith &amp;</td>
<td>John Smith and Son</td>
</tr>
<tr>
<td>Use the partners’ personal names. Do not use the name of the partnership.</td>
<td>Mr Michael John Smith</td>
<td></td>
</tr>
<tr>
<td>Superannuation Funds</td>
<td>Jane Smith Pty Ltd</td>
<td>Jane Smith Pty Ltd Superannuation Fund</td>
</tr>
<tr>
<td>Use the name of the trustee(s) of the super fund.</td>
<td>&lt;Super Fund A/C&gt;</td>
<td></td>
</tr>
</tbody>
</table>

PRIVACY STATEMENT
Personal information is collected on this form by Security Transfer Registrars Pty Ltd as the registrar for securities issuers for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. Your personal details may be disclosed to related bodies corporate, to external service providers such as mail and print providers, or as otherwise required or permitted by law. If you would like details of your personal information held by Security Transfer Registrars Pty Ltd or you would like to correct information that is inaccurate please contact them on the address on this form.